Skip to content
Ziagen(abacavir)
Epzicom, Kivexa, Triumeq, Trizivir, Ziagen (abacavir) is a small molecule pharmaceutical. Abacavir was first approved as Ziagen on 1998-12-17. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Ziagen (generic drugs available since 2012-06-18)
Combinations
Epzicom, Triumeq, Trizivir (generic drugs available since 2012-06-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abacavir sulfate
Tradename
Company
Number
Date
Products
ZIAGENViiV HealthcareN-020977 RX1998-12-17
1 products, RLD, RS
ZIAGENViiV HealthcareN-020978 RX1998-12-17
1 products, RLD, RS
Abacavir sulfate
+
Dolutegravir sodium
+
Lamivudine
Tradename
Company
Number
Date
Products
TRIUMEQViiV HealthcareN-205551 RX2014-08-22
1 products, RLD, RS
TRIUMEQ PDViiV HealthcareN-215413 RX2022-03-30
1 products, RLD, RS
Abacavir sulfate
+
Lamivudine
Tradename
Company
Number
Date
Products
EPZICOMViiV HealthcareN-021652 RX2004-08-02
1 products, RLD, RS
Abacavir sulfate
+
Lamivudine
+
Zidovudine
Tradename
Company
Number
Date
Products
TRIZIVIRViiV HealthcareN-021205 RX2000-11-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
epzicomNew Drug Application2021-02-17
triumeqNew Drug Application2021-03-23
trizivirNew Drug Application2021-02-17
ziagenNew Drug Application2020-11-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Abacavir Sulfate / Dolutegravir Sodium / Lamivudine, Triumeq, Viiv Hlthcare
92429862029-12-08DS, DP
81293852027-10-05DS, DP
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF06: Abacavir
J05AR: Antivirals for treatment of hiv infections, combinations
J05AR02: Lamivudine and abacavir
J05AR04: Zidovudine, lamivudine and abacavir
J05AR13: Lamivudine, abacavir and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
165 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201528362718123
HivD006678O98.73249118
InfectionsD007239EFO_00005443163215
LipodystrophyD008060E88.12114
Hiv-1D0154971113
TuberculosisD014376EFO_0000774A15-A19123
Cardiovascular diseasesD002318EFO_0000319I9822
Hiv-2D01549811
Hiv-associated lipodystrophy syndromeD039682EFO_100134811
Patient complianceD01034911
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21112
Lactic acidosisD000140EFO_1000036E87.20111
Aids dementia complexD015526EFO_000260811
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Acquired immunodeficiency syndromeD000163EFO_0000765B2011
Hepatitis cD006526B19.211
PsoriasisD011565EFO_0000676L4011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Wasting syndromeD019282R6411
Hepatitis bD00650911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameABACAVIR
INNabacavir
Description
Abacavir is a 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug allergen.
Classification
Small molecule
Drug classantivirals: carbocyclic nucleosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1
Identifiers
PDB
CAS-ID136470-78-5
RxCUI190521
ChEMBL IDCHEMBL1380
ChEBI ID421707
PubChem CID441300
DrugBankDB01048
UNII IDWR2TIP26VS (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 10,058 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epzicom, Triumeq, Trizivir, Ziagen
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details